Rationale, design, and baseline characteristics of a trial for the prevention of diabetic atherosclerosis using a Dpp-4 inhibitor: The study of preventive effects of alogliptin on diabetic atherosclerosis (SPEAD-A)

Journal of Atherosclerosis and Thrombosis

Volumn 20, Issue 12, 2013, Pages 893-902

  Katakami, Naoto ^a   Mita, Tomoya ^b   Yoshii, Hidenori ^c   Onuma, Tomio ^c   Kaneto, Hideaki ^a   Osonoi, Takeshi ^d   Shiraiwa, Toshihiko ^e   Kosugi, Keisuke ^f   Umayahara, Yutaka ^g   Yamamoto, Tsunehiko ^h   Yokoyama, Hiroki ⁱ   Kuribayashi, Nobuichi ^j   Jinnouchi, Hideaki ^k   Gosho, Masahiko ^l   Watada, Hirotaka ^b   Shimomura, Iichiro ^a  

^a OSAKA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b JUNTENDO UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^c JUNTENDO TOKYO KOTO GERIATRIC MEDICAL CENTER   (Japan)

^d Naka Kinen Clinic   (Japan)

^e Shiraiwa Medical Clinic   (Japan)

^f OSAKA POLICE HOSPITAL   (Japan)

^g OSAKA GENERAL MEDICAL CENTER   (Japan)

^h KANSAI ROSAI HOSPITAL   (Japan)

ⁱ Jiyugaoka Medical Clinic   (Japan)

^j Misaki Naika Clinic   (Japan)

^k Jinnouchi Hospital   (Japan)

^l AICHI MEDICAL UNIVERSITY   (Japan)

more..

Author keywords

Alogliptin; Atherosclerosis; Diabetes; DPP 4; Intima media thickness (IMT)

Indexed keywords

ALOGLIPTIN; HEMOGLOBIN A1C;

ADULT; ARTERIAL WALL THICKNESS; ARTICLE; CARDIOVASCULAR DISEASE; CONTROLLED STUDY; DIABETIC ATHEROSCLEROSIS; DIABETIC NEPHROPATHY; DISEASE COURSE; DYSLIPIDEMIA; ECHOGRAPHY; FEMALE; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; OPEN STUDY; PARALLEL DESIGN; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; UNSPECIFIED SIDE EFFECT;

AGED; ATHEROSCLEROSIS; DIABETES COMPLICATIONS; DIPEPTIDYL-PEPTIDASE IV INHIBITORS; FEMALE; HUMANS; MALE; MIDDLE AGED; PIPERIDINES; URACIL;

EID: 84890854371     PISSN: 13403478     EISSN: 18803873     Source Type: Journal    
DOI: 10.5551/jat.18333     Document Type: Article

References (31)

1. Haffner SM, Lehto S, Rönnemaa T, Pyörälä K, Laakso M: Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. N Engl J Med, 1998; 339: 229-234
2. Stamler J, Vaccaro O, Neaton JD, Wentworth D: Diabetes, other risk factors, and 12-year cardiovascular mortality for men screened in the Multiple Risk Factor Interven-tional trial. Diabetes Care, 1993; 16: 434-444
3. Laakso M: Glycemic control and the risk for coronary heart disease in patients with non-insulin-dependent diabetes mellitus. The Finnish studies. Ann Intern Med, 1996; 124: 127-130
4. UK Prospective Diabetes Study (UKPDS) Group: Intensive blood-glucose control with sulfonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes. Lancet, 1998; 352: 837-853
5. UK Prospective Diabetes Study (UKPDS) Group: Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet, 1998; 352: 854-865
6. Bolen S, Feldman L, Vassy J, Wilson L, Yeh H-C, Mari-nopoulos S, Wiley C, Selvin E, Wilson R, Bass EB, Bran-cati FL: Sytematic review: comparative effectiveness and safety of oral medications for type 2 diabetes. Ann Int Med, 2007; 147: 386-399
7. Barrera JG, Sandoval DA, D'Alessio DA, Seeley RJ: GLP-1 and energy balance: an integrated model of short-term and long-term control. Nat Rev Endocrinol, 2011; 7: 507-516
8. Lovshin JA, Drucker DJ: Incretin-based therapies for type 2 diabetes mellitus. Nat Rev Endocrinol, 2009; 5: 262-269
9. Ban K, Noyan-Ashraf MH, Hoefer J, Bolz SS, Drucker DJ, Husain M: Cardioprotective and vasodilatory actions of glucagon-like peptide 1 receptor are mediated through both glucagon-like peptide 1 receptor dependent and independent pathways. Circulation, 2008; 117: 2340-2350
10. Liu H, Dear AE, Knudsen LB, Simpson RW: A long-acting glucagon-like peptide-1 analogue attenuates induction of plasminogen activator inhibitor type-1 and vascular adhesion molecules. J Endocrinol, 2009; 201: 59-66
11. Fadini G P, Avogaro A: Cardiovascular effects of DPP-4 inhibition: beyond GLP-1. Vascul Pharmacol, 2011; 55: 10-16
12. Grieve DJ, Cassidy RS, Green BD: Emerging cardiovascular actions of the incretin hormone glucagon-like pep-tide-1: potential therapeutic benefits beyond glycaemic control? Br J Pharmacol, 2009; 157: 1340-1351
13. Arakawa M, Mita T, Azuma K, Ebato C, Goto H, Nomi-yama T, Fujitani Y, Hirose T, Kawamori R, Watada H: Inhibition of monocyte adhesion to endothelial cells and attenuation of atherosclerotic lesion by a glucagon-like peptide-1 receptor agonist, exendin-4. Diabetes, 2010; 59: 1030-1037
14. Ervinna N, Mita T, Yasunari E, Azuma K, Tanaka R, Fujimura S, Sukmawati D, Nomiyama T, Kanazawa A, Kawamori R, Fujitani Y, Watada H: Anagliptin, a DPP-4 Inhibitor, Suppresses Proliferation of Vascular Smooth Muscles and Monocyte Inflammatory Reaction and Attenuates Atherosclerosis in Male apo E-Deficient Mice. Endocrinology, 2013; 154: 1260-1270
15. Feng J, Zhang Z, Wallace MB, Stafford JA, Kaldor SW, Kassel DB, Navre M, Shi L, Skene RJ, Asakawa T, Takeu-chi K, Xu R, Webb DR, Gwaltney SL 2nd: Discovery of alogliptin: a potent, selective, bioavailable, and efficacious inhibitor of dipeptidyl peptidase IV. J Med Chem, 2007; 50: 2297-2300
16. DeFronzo RA, Fleck PR, Wilson CA, Mekki Q: Efficacy and safety of the dipeptidyl peptidase-4 inhibitor alo-gliptin in patients with type 2 diabetes and inadequate glycemic control: a randomized, double-blind, placebo-controlled study. Diabetes Care, 2008; 31: 2315-2317
17. Pratley RE, Reusch JE, Fleck PR, Wilson CA, Mekki Q: Efficacy and safety of the dipeptidyl peptidase-4 inhibitor alogliptin added to pioglitazone in patients with type 2 diabetes: a randomized, double-blind, placebo-controlled study. Curr Med Res Opin, 2009; 25: 2361-2371
18. Shah Z, Kampfrath T, Deiuliis JA, Zhong J, Pineda C, Ying Z, Xu X, Lu B, Moffatt-Bruce S, Durairaj R, Sun Q, Mihai G, Maiseyeu A, Rajagopalan S: Long-term dipepti-dyl-peptidase 4 inhibition reduces atherosclerosis and inflammation via effects on monocyte recruitment and chemotaxis. Circulation, 2011; 124: 2338-2349
19. Ta NN, Schuyler CA, Li Y, Lopes-Virella M F, Huang Y: DPP-4 (CD26) Inhibitor Alogliptin Inhibits Atheroscle-rosis in Diabetic Apolipoprotein E-Deficient Mice. Car-diovasc Pharmacol, 2011; 58: 157-166
20. Yamasaki Y, Kodama M, Nishizawa H, Sakamoto K, Mat-suhisa M, Kajimoto Y, Kosugi K, Shimizu Y, Kawamori R, Hori M: Carotid intimamedia thickness in Japanese type 2 diabetic subjects: Predictors of progression and relationship with incident coronary heart disease. Diabetes Care, 2000; 23: 1310-1315
21. Mitsuhashi N, Onuma T, Kubo S, Takayanagi N, Honda M, Kawamori R: Coronary artery disease and carotid artery intima-media thickness in Japanese type 2 diabetic patients. Diabetes Care, 2002; 25: 1308-1312
22. The Japan Diabetes Society: Treatment Guide for Diabetes, ed by the Editorial Committee Members of "Treatment Guide for Diabetes" (Araki E, Iwamoto Y, Kad-owaki T, Kashiwagi A, Kitaoka M, Nanjo K, Tajima N), Bunkodo Co., Ltd., Tokyo, Japan, 2010
23. Terminology and Diagnostic Criteria Committee, Japan Society of Ultrasonics in Medicine. Subcommittee for Preparing Guidelines for Ultrasound Diagnosis of Carotid Artery: Standard method for ultrasound evaluation of carotid artery lesions. Jpn J Med Ultrasonics, 2009; 36: 501-518
24. Yanase T, Nasu S, Mukuta Y, Shimizu Y, Nishihara T, Okabe T, Nomura M, Inoguchi T, Nawata H: Evaluation of a new carotid intima-media thickness measurement by B-Mode ultrasonography using an innovative measurement software, Intimascope. Am J Hypertens, 2006; 19: 1206-1212
25. Yokoyama H, Katakami N, Yamasaki Y: Recent advances of intervention to inhibit progression of carotid intima-media thickness in patients with type 2 diabetes mellitus. Stroke, 2006; 37: 2420-2427
26. Tahrani AA, Bailey CJ, Del Prato S, Barnett AH: Management of type 2 diabetes: new and future developments in treatment. Lancet, 2011; 378: 182-197
27. O'Leary DH, Polak JF, Kronmal RA, Manolio TA, Burke GL, Wolfson SK Jr: Cardiovascular Health Study Collaborative Research Group. Carotid-artery intima and media thickness as a risk factor for myocardial infarction and stroke in older adults. N Engl J Med, 1999; 340: 14-22
28. Lorenz MW, Markus HS, Bots ML, Rosvall M, Sitzer M: Prediction of clinical cardiovascular events with carotid intima-media thickness: a systematic review and meta-analysis. Circulation, 2007; 115: 459-467
29. Hodis HN, Mack WJ, LaBree L, Selzer RH, Liu CR, Liu CH, Azen SP: The role of carotid arterial intima-media thickness in predicting clinical coronary events. Ann Intern Med, 1998; 128: 262-269
30. Barbieri M, Rizzo MR, Marfella R, Boccardi V, Esposito A, Pansini A, Paolisso G: Decreased carotid atherosclerotic process by control of daily acute glucose fluctuations in diabetic patients treated by DPP-IV inhibitors. Atherosclerosis, 2013; 227: 349-354
31. Rizzo MR, Barbieri M, Marfella R, Paolisso G: Reduction of oxidative stress and inflammation by blunting daily acute glucose fluctuations in patients with type 2 diabetes: role of dipeptidyl peptidase-IV inhibition. Diabetes Care, 2012; 35: 2076-2078